Global Diabetes Pen Market – Industry Trends and Forecast to 2031

Inhaltsverzeichnis anfordernInhaltsverzeichnis anfordern Mit Analyst sprechen Mit Analyst sprechen Jetzt kaufenJetzt kaufen Vor dem Kauf anfragen Vorher anfragen Kostenloser Beispielbericht Kostenloser Beispielbericht

Global Diabetes Pen Market – Industry Trends and Forecast to 2031

  • Healthcare
  • Upcoming Reports
  • Jan 2024
  • Global
  • 350 Seiten
  • Anzahl der Tabellen: 60
  • Anzahl der Abbildungen: 220

Global Diabetes Pen Market

Marktgröße in Milliarden USD

CAGR :  % Diagram

Diagramm Prognosezeitraum
2024 –2031
Diagramm Marktgröße (Basisjahr)
USD 10.13 Billion
Diagramm Marktgröße (Prognosejahr)
USD 22.99 Billion
Diagramm CAGR
%
Diagramm Wichtige Marktteilnehmer
  • AstraZeneca
  • BD
  • Eli Lilly and Company
  • Biocon
  • Sanofi

Global Diabetes Pen Market, By Product Type (Insulin Pens, Insulin Pen Needle), Usage (Reusable Pens, Disposable Pens), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics) - Industry Trends and Forecast to 2031.

Diabetes Pen Market

 

Diabetes Pen Market Analysis and Size

The rise in the population of diabetes patients across the globe is among the important factors expected to intensify the growth and demand of the diabetes pen market. In addition, the high demand for human insulin analog and the rise in the incidence of needle stick injury are also expected to contribute to the growth in the market. Also, the reimbursement for diabetes management and rapid technological advancement in the production of diabetes pens are also likely to enhance the growth of the market. Furthermore, the rise in the particular treatments for cancer along with easy access to a large proportion of medicines are also among the significant factors expected to fuel the growth of the diabetes pen market.

Data Bridge Market Research analyzes that the global diabetes pen market, which was USD 10.13 billion in 2023, is likely to reach USD 22.99 billion by 2031 and is expected to undergo a CAGR of 8.9% during the forecast period. “Retail Pharmacy" dominates the distribution channel segment of the market. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Product Type (Insulin Pens, Insulin Pen Needle), Usage (Reusable Pens, Disposable Pens), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa

Market Players Covered

AstraZeneca (U.K.), BD (U.S.), Eli Lilly and Company (U.S.), Biocon (India), Sanofi (France), Jiangsu Delfu Medical Device Co., Ltd. (China), Owen Mumford (U.K.), Wockhardt Limited (India) (India), Smiths Group plc (U.K.), Nipro Europe Group Companies (Netherlands), Novo Nordisk India Pvt Ltd. (India), InjexUK (U.K.), MannKind Corporation (U.S.), Bristol-Myers Squibb Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Copernicus (Poland), Ypsomed AG (Switzerland), HTL-STREFA S.A. (Poland), Merck & Co., Inc. (U.S.), Bayer AG (Germany)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment in the development of advanced technologies
  • Surging drug approvals and launches.

Market Definition

The diabetes pens are largely used to inject insulin for the treatment of diabetes. It is basically composed of an insulin cartridge, which is incorporated or bought separately, and a dial to quantify the dose, and is also used with disposable pen needles to deliver the dose.

Global Diabetes Pen Market Dynamics

Drivers

  • Growing Prevalence of Diabetes

The increasing global incidence of diabetes is a major driver for the diabetes pen market. As more individuals are diagnosed with diabetes, the demand for convenient and effective insulin delivery devices like diabetes pens is on the rise.

  • Advancements in Diagnostic Technologies

Ongoing advancements in diabetes pen technologies, such as the development of smart insulin pens and connected devices, are enhancing user experience and adherence to insulin therapy. These innovations contribute to market growth.

  • Patient Preference for Non-invasive Delivery

Patients often prefer non-invasive and user-friendly insulin delivery options. Diabetes pens offer a less invasive alternative to traditional insulin syringes, driving their adoption among patients.

 Opportunities

  • Increasing Awareness and Education

Opportunities lie in increasing awareness about the benefits of diabetes pens and providing education to healthcare professionals and patients. This can enhance acceptance and adoption.

  • Focus on Emerging Markets

There is significant growth potential in emerging markets where diabetes prevalence is rising. Manufacturers can explore opportunities in these regions by offering cost-effective and user-friendly diabetes pen solutions.

Restraints

  • High Cost of Smart Insulin Pens

While smart insulin pens offer advanced features such as dose tracking and connectivity, they can be expensive. The high cost of these devices can limit their adoption, particularly in regions with budget constraints.

  • Limited Adoption in Developing Regions

Access to advanced healthcare technologies, including diabetes pens, may be limited in developing regions due to economic constraints and inadequate healthcare infrastructure.

Global Diabetes Pen Market Scope

The diabetes pen market is segmented on the basis of product type, usage, application and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Product type

  •  Insulin Pens
  • Insulin Pen Needle.

Usage

  • Reusable Pens
  • Disposable Pens

Application

  • Type 1 Diabetes
  •  Type 2 Diabetes

Distribution Channel

  • Hospital Pharmacy
  •  Retail Pharmacy
  • Online Sales
  • Diabetes Clinics.

Diabetes Pen Market Regional Analysis/Insights

The diabetes pen market is analyzed and market size insights and trends are provided by country, product type, usage, application and distribution channel as referenced above.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Kuwait, Egypt, and rest of Middle East & Africa.

North America is expected to dominate the market due to the rise in the diabetic population and better awareness and reimbursement policy for diabetes management.

Asia-Pacific is expected to show the fastest growth due to surging government initiatives to spread awareness and increase the geriatric population in this region. Also, the development of healthcare infrastructure will further propel the market's growth rate in this region.

The country section of the report also provides individual market-impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Healthcare Infrastructure growth Installed base and New Technology Penetration

The diabetes pen market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for diabetes pen market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on diabetes pen market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Diabetes Pen Market Share Analysis

The diabetes pen market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to diabetes pen market.

Some of the major players operating in the diabetes pen market are:

  • AstraZeneca (U.K.)
  • BD (U.S.)
  • Eli Lilly and Company (U.S.)
  • Biocon (India)
  • Sanofi (France)
  • Jiangsu Delfu Medical Device Co., Ltd. (China)
  • Owen Mumford (U.K.)
  • Wockhardt Limited (India) (India)
  • Smiths Group plc (U.K.)
  • Nipro Europe Group Companies (Netherlands)
  • Novo Nordisk India Pvt Ltd. (India)
  • InjexUK (U.K.)
  • MannKind Corporation (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Copernicus (Poland)
  • Ypsomed AG (Switzerland)
  • HTL-STREFA S.A. (Poland)
  • Merck & Co., Inc. (U.S.)
  • Bayer AG (Germany)


SKU-

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

  • Interaktives Datenanalyse-Dashboard
  • Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
  • Zugriff für Research-Analysten für Anpassungen und Abfragen
  • Konkurrenzanalyse mit interaktivem Dashboard
  • Aktuelle Nachrichten, Updates und Trendanalyse
  • Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Demo anfordern

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

The market is segmented based on , By Product Type (Insulin Pens, Insulin Pen Needle), Usage (Reusable Pens, Disposable Pens), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics) - Industry Trends and Forecast to 2031. .
The Global Diabetes Pen Market size was valued at USD 10.13 USD Billion in 2023.
The Global Diabetes Pen Market is projected to grow at a CAGR of 8.9% during the forecast period of 2024 to 2031.
The major players operating in the market include AstraZeneca, BD, Eli Lilly and Company, Biocon, Sanofi, Jiangsu Delfu Medical Device Co. , Owen Mumford, Wockhardt Limited, Smiths Group plc, Nipro Europe Group Companies, Novo Nordisk India , InjexUK, MannKind Corporation, BristolMyers Squibb Company, F. HoffmannLa Roche , Copernicus, Ypsomed AG, HTLSTREFA S.A., Merck & Co. , Bayer AG.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa.